High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Peter S. Conti; John Hilton; Dean F. Wong; Mian M. Alauddin; Robert F. Dannals; Hayden T. Ravert; Alan A. Wilson; James H. Anderson

doi:10.1016/0969-8051(94)90176-7

High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Peter S. Conti
, John Hilton
, Dean F. Wong
, Mian M. Alauddin
, Robert F. Dannals
, Hayden T. Ravert
, Alan A. Wilson
, James H. Anderson

Precision Radiotheranostics Translation Center (PRTC)

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

Original language	English
Pages (from-to)	1045-1051
Number of pages	7
Journal	Nuclear Medicine and Biology
Volume	21
Issue number	8
DOIs	https://doi.org/10.1016/0969-8051(94)90176-7
State	Published - Nov 1994

Access to Document

10.1016/0969-8051(94)90176-7

Cite this

@article{c7a7467b4f2d4cf7ab6675eb3fbd6540,

title = "High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies",

abstract = "The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.",

author = "Conti, \{Peter S.\} and John Hilton and Wong, \{Dean F.\} and Alauddin, \{Mian M.\} and Dannals, \{Robert F.\} and Ravert, \{Hayden T.\} and Wilson, \{Alan A.\} and Anderson, \{James H.\}",

note = "Funding Information: Acknowledgements-This work was supported in part by NIH grants CA 37870-08a nd CA 54112-01S. pecial thanks to Mr Robert Smoot for assistancein radiotracer production.",

year = "1994",

month = nov,

doi = "10.1016/0969-8051(94)90176-7",

language = "English",

volume = "21",

pages = "1045--1051",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

number = "8",

}

TY - JOUR

T1 - High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

AU - Conti, Peter S.

AU - Hilton, John

AU - Wong, Dean F.

AU - Alauddin, Mian M.

AU - Dannals, Robert F.

AU - Ravert, Hayden T.

AU - Wilson, Alan A.

AU - Anderson, James H.

N1 - Funding Information: Acknowledgements-This work was supported in part by NIH grants CA 37870-08a nd CA 54112-01S. pecial thanks to Mr Robert Smoot for assistancein radiotracer production.

PY - 1994/11

Y1 - 1994/11

N2 - The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

AB - The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

UR - https://www.scopus.com/pages/publications/0028618661

U2 - 10.1016/0969-8051(94)90176-7

DO - 10.1016/0969-8051(94)90176-7

M3 - Article

C2 - 9234362

AN - SCOPUS:0028618661

SN - 0969-8051

VL - 21

SP - 1045

EP - 1051

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 8

ER -

High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this